Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating reiterated by research analysts at Numis Securities Ltd in a report issued on Monday. They presently have a GBX 267 ($3.30) price target on the stock. Numis Securities Ltd’s price objective suggests a potential upside of 120.66% from the stock’s current price.

ERGO has been the topic of a number of other reports. Stifel Nicolaus reissued a “buy” rating and issued a GBX 271 ($3.35) price target on shares of Ergomed PLC in a report on Friday, September 2nd. N+1 Singer reissued a “buy” rating on shares of Ergomed PLC in a report on Monday, September 26th.

Shares of Ergomed PLC (LON:ERGO) opened at 120.75 on Monday. Ergomed PLC has a 1-year low of GBX 117.00 and a 1-year high of GBX 172.00. The company’s market capitalization is GBX 37.57 million. The stock has a 50 day moving average of GBX 120.15 and a 200-day moving average of GBX 131.80.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About Ergomed PLC

Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs.

Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with's FREE daily email newsletter.